Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

By Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1375-1383

Informa Healthcare

Access to resources Recommend Favorite

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

By Farlow Martin R.   Alva Gus   Meng Xiangyi   Olin Jason T.  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 263-269

Informa Healthcare

Access to resources Recommend Favorite

Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study

By Mets Tony   Vandewoude Maurits   Jacquy Jean   Deblander Anne   MacDonald Karen   Sloesen Anne   Abraham Ivo    

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2485-2501

Informa Healthcare

Access to resources Recommend Favorite

A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease

By  

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, Vol. 30, Iss. 9, 2015-09 ,pp. : 965-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

By Farlow Martin R.   Grossberg George   Gauthier Serge   Meng Xiangyi   Olin Jason T.  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2441-2447

Informa Healthcare

Access to resources Recommend Favorite